Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03596710

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Jonsson Comprehensive Cancer Center · Academic / Other
Sex
Male
Age
—
Healthy volunteers
Not accepted

Summary

This trial studies image-guided biopsies work in identifying mechanisms of resistance in participants with castration resistant prostate cancer that has spread to other places in the body and who are undergoing radioligand therapy (RLT). Tissue sample collected from a biopsy may help determine why response to RLT varies among patients, and this may help researchers to find better treatments for advanced prostate cancer.

Detailed description

PRIMARY OBJECTIVES: I. Proportion of metastatic castration resistant prostate cancer (mCRPC) patients with altered signaling pathways after radioligand therapy assessed by phospho-proteomics of biopsy samples. SECONDARY OBJECTIVES: I. Generation of patient derived xenograft (PDX) models to determine if tumor levels of activity for individual adaptive pathways are related to the best prostate specific antigen (PSA) response. II. Sequencing to identify frequently mutated genes such as TP53 and ATM. OUTLINE: Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.

Conditions

Interventions

TypeNameDescription
PROCEDUREImage Guided BiopsyUndergo image guided biopsy

Timeline

Start date
2018-06-14
Primary completion
2021-06-14
Completion
2022-06-14
First posted
2018-07-24
Last updated
2020-07-23

Source: ClinicalTrials.gov record NCT03596710. Inclusion in this directory is not an endorsement.